heiDATA

Metrics

189,636 Downloads

Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

File Type: Document

41 to 50 of 966 Results

Vardarli_Suppl. Table 12.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 219.2 KB - MD5: f9d8e1df71b9731cc42906df4abab368 Suppl. Table 12. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 11.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 216.4 KB - MD5: 37c1389d7ef9b12de77e87300a627604 Suppl. Table 11. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 10.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 219.1 KB - MD5: b0d44cc6d4f377511600f93c84adb67c Suppl. Table 10. Trim-and-fill results for trials investigating adrenal insufficiency grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 1.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 625.1 KB - MD5: 591d49eda306f69d5fd24a059d714ccc Suppl. Table 1. Checklist according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monoth...
Vardarli_Suppl Fig 9.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 123.5 KB - MD5: bca376270d42ef0d17b56dc422bd4937 Suppl. Fig. 9. Forest plot for subgroups of ICI types trials investigating hyperthyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 8.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.8 KB - MD5: 57e8d84f42b25d9f50320342f7c3ccee Suppl. Fig. 8. Forest plot for cumulative meta-analysis for trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 7.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 124.3 KB - MD5: 529ade845823207e4f85f60a376b1ace Suppl. Fig. 7. Forest plot for subgroups of ICI types trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 6.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 80.3 KB - MD5: 278b753250fa90715cc5806ab1784d4c Suppl. Fig. 6. Forest plot for cumulative meta-analysis for trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 54.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 69.3 KB - MD5: dbf03154a7caaecc0ea565a1d74fd1cd Suppl. Fig. 54. Galbraith plot for trials investigating insulin-dependent diabetes mellitus grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials
Vardarli_Suppl Fig 53.pdf Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data] Adobe PDF - 63.9 KB - MD5: a78f4750989043bac256c01eb6e1d727 Suppl. Fig. 53. Funnel plot with trim-and-fill for trials investigating insulin-dependent diabetes mellitus grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 12.pdf

Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]

Adobe PDF - 219.2 KB -

Suppl. Table 12. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 11.pdf

Adobe PDF - 216.4 KB -

Suppl. Table 11. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 10.pdf

Adobe PDF - 219.1 KB -

Suppl. Table 10. Trim-and-fill results for trials investigating adrenal insufficiency grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl. Table 1.pdf

Adobe PDF - 625.1 KB -

Suppl. Table 1. Checklist according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monoth...

Vardarli_Suppl Fig 9.pdf

Adobe PDF - 123.5 KB -

Suppl. Fig. 9. Forest plot for subgroups of ICI types trials investigating hyperthyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 8.pdf

Adobe PDF - 80.8 KB -

Suppl. Fig. 8. Forest plot for cumulative meta-analysis for trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 7.pdf

Adobe PDF - 124.3 KB -

Suppl. Fig. 7. Forest plot for subgroups of ICI types trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 6.pdf

Adobe PDF - 80.3 KB -

Suppl. Fig. 6. Forest plot for cumulative meta-analysis for trials investigating hypothyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Vardarli_Suppl Fig 54.pdf

Adobe PDF - 69.3 KB -

Suppl. Fig. 54. Galbraith plot for trials investigating insulin-dependent diabetes mellitus grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials

Vardarli_Suppl Fig 53.pdf

Adobe PDF - 63.9 KB -

Suppl. Fig. 53. Funnel plot with trim-and-fill for trials investigating insulin-dependent diabetes mellitus grade3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.

Add Data

Share Dataverse

Link Dataverse

Reset Modifications